In this historic moment, in which everything is evolving, in order to make the sharing of sure and real information easier, Fondazione Gianni Benzi keeps on its commitment in the initiative against misinformation, by providing the community with scientific verified news.
In particular, today we want to share a news related to the research of possible therapies to treat the Coronavirus infection.
AIFA and Gilead have announced that Italy will take part in two Phase 3 studies promoted by Gilead Sciences to evaluate the efficacy and safety of the experimental antiviral Remdesivir in adults admitted to hospital with the COVID-19 diagnosis.
The studies will be initially led at Ospedale Sacco in Milan, the Policlinico in Pavia, Azienda Ospedaliera in Padova, Azienda Ospedaliera Universitaria in Parma and Istituto Nazionale di Malattie Infettive Lazzaro Spallanzani. Other centers, in regions where the Coronavirus infection incidence is high, are being identified in collaboration with AIFA in order to include them in the studies.
Remdesivir is experimentally used on human beings also against the Ebola infection and in in-vitro tests it has showed a particular activity against other kinds of Coronavirus, like SARS and MERS. This medicine has also been administered to the first American patient affected by SARS-COV-2 and in some Chinese hospitals a trial will be led on about 800 patients.
The medicine has not been approved by the regulatory authorities for the therapeutic use yet and it is provided for compassionate use - not included in the clinical trials – for the emergency treatment of only patients affected by COVID-19 in serious conditions and without valid therapeutic alternatives.
The medical and scientific community is making several efforts to face the emergency, as well as the regulatory authorities are trying to facilitate the actions that need to be led.
We will keep you updated!